Cargando…
Prolonged ketosis and glycosuria secondary to SGLT2 inhibitor therapy
Clinicians should be aware of the potential for the pharmacologic activity of SGLT2 inhibitors to persist long after the standard drug clearance period of five half‐lives, the typical duration used to guide pre‐operative medication recommendations.
Autores principales: | Bobrowski, David, Kumar, Reha, Wu, Peter E., Lapointe‐Shaw, Lauren |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8577244/ https://www.ncbi.nlm.nih.gov/pubmed/34786197 http://dx.doi.org/10.1002/ccr3.5057 |
Ejemplares similares
-
THU389 Euglycemic Diabetic Ketoacidosis With Prolonged Ketosis Due To SGLT-2 Inhibitor
por: Viera Feliciano, Natalia, et al.
Publicado: (2023) -
SGLT2-inhibitors; more than just glycosuria and diuresis
por: Fathi, Amir, et al.
Publicado: (2020) -
Hereditary renal glycosuria, diabetes and responses to SGLT2 inhibitor
por: Ren, Qian, et al.
Publicado: (2022) -
Prolonged Ketosis in a Patient With Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin
por: Pujara, Shreya, et al.
Publicado: (2017) -
Bittersweet: infective complications of drug-induced glycosuria in patients with diabetes mellitus on SGLT2-inhibitors: two case reports
por: Bartolo, Caroline, et al.
Publicado: (2021)